Phase 1 Oesophageal Cancer Trial, Recruiting NCT06414902 Sponsor: M.D. Anderson Cancer Center Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 1 Oesophageal Cancer Trial, Recruiting

NCT06414902
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older.
  • People who have locally advanced cancer of the esophagus (the tube connecting the throat to the stomach).
  • People who have a confirmed esophageal cancer tumor larger than 2 cm that has not yet been treated, and who are planned to receive both medication-based treatment and radiation therapy together as their main treatment.
  • People who are able to sign a written consent form agreeing to take part, following the institution's guidelines.
  • Women who could become pregnant must have a negative pregnancy test (blood or urine) within one week before the investigational scan takes place.
  • Women who could become pregnant must agree to use an approved form of birth control before joining the trial and throughout their participation. Approved methods include hormonal contraception (such as pills, injections, implants, patches, or vaginal rings), an intrauterine device (IUD), tubal ligation, hysterectomy, a partner's vasectomy, implantable or injectable contraceptives, or condoms used with spermicide. Completely avoiding sexual activity for the full duration of the trial is also acceptable. Methods such as the rhythm method or withdrawal are not considered acceptable.

Who may not be able to join:

  • People who weigh 400 pounds (approximately 181 kg) or more, or whose body size or physical condition would prevent the required scans from being completed.
  • Women who are pregnant or currently breastfeeding, because the investigational scan agent may carry risks to a developing baby or a nursing infant.
  • People who have had an allergic reaction to intravenous (IV) contrast dye in the past.
  • People whose kidney function test result (called eGFR) is below 40 within the month before receiving the investigational scan agent.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Steven Lin, MD, M.D. Anderson Cancer Center

Phone: (713) 563-8490

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
4 September 2024
Est. completion
1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Safety and adverse events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov